Orphazyme AS (CHIX:ORPHAC) Net Change in Cash : kr-747.69 Mil (TTM As of Jun. 2022)

View and export this data going back to 2021. Start your Free Trial

What is Orphazyme AS Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Orphazyme AS's Net Change in Cash for the three months ended in Jun. 2022 was kr-116.30 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Jun. 2022 was kr-747.69 Mil.

Orphazyme AS Net Change in Cash Historical Data

The historical data trend for Orphazyme AS's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Orphazyme AS Net Change in Cash Chart

Orphazyme AS Annual Data

Trend

Jun14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Net Change in Cash

Get a 7-Day Free Trial

617.39

-237.03

-271.12

603.34

-624.67

Orphazyme AS Quarterly Data
	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22
Net Change in Cash	Get a 7-Day Free Trial									486.86	116.48	6.72	-631.39	-116.30

Orphazyme AS Net Change in Cash Calculation

Orphazyme AS's Net Change in Cash for the fiscal year that ended in Dec. 2021 is calculated as

Net Change in Cash	=	Cash Flow from Operations	+	Cash Flow from Investing	+	Cash Flow from Financing	+	Effect of Exchange Rate Changes
	=	-602.571	+	0.046	+	-30.344	+	8.195
	=	-624.67

Orphazyme AS's Net Change in Cash for the quarter that ended in Jun. 2022

Net Change in Cash = Cash Flow from Operations + Cash Flow from Investing + Cash Flow from Financing + Effect of Exchange Rate Changes

= -116.472 + 0 + 5.31 + -5.138

= -116.30

Net Change in Cash for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-747.69 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Orphazyme AS Net Change in Cash Related Terms
Thank you for viewing the detailed overview of Orphazyme AS's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Orphazyme AS (CHIX:ORPHAC) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Orphazyme AS (CHIX:ORPHAc) » Definitions » Net Change in Cash

Comparable Companies

Traded in Other Exchanges

N/A

Address

Ole Maaloes Vej 3, Copenhagen, DNK, DK-2200

Website

https://www.orphazyme.com

Orphazyme AS is a late-stage biopharmaceutical company engaged in the development and commercialization of novel therapeutics for the treatment of neurodegenerative rare diseases. The company's lead candidate, Arimoclomol, is in development for severe orphan diseases: Niemann-Pick disease Type C (NPC), Amyotrophic Lateral Sclerosis (ALS), and Inclusion Body Myositis (IBM).

Orphazyme AS (CHIX:ORPHAC) Headlines

No Headlines